Preface on Neoadjuvant Therapy for Ovarian Cancer1
Neoadjuvant therapy for ovarian cancer
Chinese Clinical Oncology
2018;
7
(6)
:54
.
(01 December 2018)
Review Article on Neoadjuvant Therapy for Ovarian Cancer1
Neoadjuvant therapy: theoretical, biological and medical consideration
Chinese Clinical Oncology
2018;
7
(6)
:55
.
(01 December 2018)
Principles of clinical management of ovarian cancer
Chinese Clinical Oncology
2018;
7
(6)
:56
.
(01 December 2018)
Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages
Chinese Clinical Oncology
2018;
7
(6)
:57
.
(01 December 2018)
Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation
Chinese Clinical Oncology
2018;
7
(6)
:58
.
(01 December 2018)
Pathological response of ovarian cancer to neoadjuvant chemotherapy
Chinese Clinical Oncology
2018;
7
(6)
:59
.
(01 December 2018)
Original Article
Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas
Chinese Clinical Oncology
2018;
7
(6)
:60
.
(01 December 2018)
Review Article
Immunotherapy: a glimmer of hope for metastatic prostate cancer
Chinese Clinical Oncology
2018;
7
(6)
:61
.
(01 December 2018)
Case Report
Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report
Chinese Clinical Oncology
2018;
7
(6)
:62
.
(01 December 2018)
Meet the Professor2
Douglas G. McNeel: stay current reading research literature, there is no substitute for hard work!
Chinese Clinical Oncology
2018;
7
(6)
:63
.
(01 December 2018)
Disclosure:
1. The series “Neoadjuvant Therapy for Ovarian Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Evgeny Imyanitov served as the unpaid Guest Editor for the series.
2. The series “Meet the Professor” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding.
